6/17
08:05 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $99.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $99.00. They now have a "buy" rating on the stock.
6/5
08:43 am
mrus
Merus (NASDAQ: MRUS) had its price target lowered by analysts at Bank of America Co. from $80.00 to $76.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target lowered by analysts at Bank of America Co. from $80.00 to $76.00. They now have a "buy" rating on the stock.
6/4
10:06 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $54.00 to $67.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $54.00 to $67.00. They now have a "buy" rating on the stock.
6/4
10:06 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $84.00 to $91.00. They now have an "outperform" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $84.00 to $91.00. They now have an "outperform" rating on the stock.
6/4
09:05 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Truist Financial Co. from $69.00 to $88.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Truist Financial Co. from $69.00 to $88.00. They now have a "buy" rating on the stock.
6/3
02:30 pm
mrus
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
Low
Report
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
6/2
12:30 pm
mrus
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
Low
Report
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
5/29
09:30 pm
mrus
Merus Announces Pricing of Upsized Public Offering of Common Shares
Medium
Report
Merus Announces Pricing of Upsized Public Offering of Common Shares
5/29
08:00 am
mrus
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
Low
Report
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
5/28
04:01 pm
mrus
Merus N.V. Announces Proposed Public Offering of Common Shares
Low
Report
Merus N.V. Announces Proposed Public Offering of Common Shares
5/28
12:07 pm
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Guggenheim from $57.00 to $93.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Guggenheim from $57.00 to $93.00. They now have a "buy" rating on the stock.
5/28
10:55 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $65.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $65.00 to $90.00. They now have a "buy" rating on the stock.
5/28
07:00 am
mrus
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
High
Report
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
5/24
08:04 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
High
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
5/24
08:04 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
High
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
5/24
08:04 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Bank of America Co. from $52.00 to $61.00. They now have a "buy" rating on the stock.
High
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Bank of America Co. from $52.00 to $61.00. They now have a "buy" rating on the stock.
5/23
05:00 pm
mrus
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
High
Report
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
5/23
05:00 pm
mrus
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
High
Report
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
5/22
03:07 am
mrus
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/22
03:07 am
mrus
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/15
12:06 am
mrus
Merus (NASDAQ: MRUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Merus (NASDAQ: MRUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/13
08:09 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
5/13
08:00 am
mrus
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
Low
Report
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
5/9
08:17 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
5/8
04:15 pm
mrus
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
Medium
Report
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update